Livopan 50 % v/v / 50 % v/v Norja - norja - Statens legemiddelverk

livopan 50 % v/v / 50 % v/v

aga ab - dinitrogenoksid / oksygen - medisinsk gass, komprimert - 50 % v/v / 50 % v/v

Steripet 250 MBq/ ml Norja - norja - Statens legemiddelverk

steripet 250 mbq/ ml

ge healthcare b.v. - fludeoksyglukose (18f) - injeksjonsvæske, oppløsning - 250 mbq/ ml

Regkirona Euroopan unioni - norja - EMA (European Medicines Agency)

regkirona

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immune sera og immunglobuliner, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Ronapreve Euroopan unioni - norja - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 og 5.

Paxlovid Euroopan unioni - norja - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Xevudy Euroopan unioni - norja - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - immune sera og immunglobuliner, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Tyenne Euroopan unioni - norja - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressive - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Co-Renitec 20 mg / 12.5 mg Norja - norja - Statens legemiddelverk

co-renitec 20 mg / 12.5 mg

orifarm as - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg

Renitec Comp 20 mg / 12.5 mg Norja - norja - Statens legemiddelverk

renitec comp 20 mg / 12.5 mg

n.v. organon - kloosterstraat - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg

Renitec Comp Mite 20 mg / 6 mg Norja - norja - Statens legemiddelverk

renitec comp mite 20 mg / 6 mg

merck sharp & dohme b.v. - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 6 mg